Table 3.
Summaries of the studies on ultrasound-responsive droplets.
| Core | Shell | Cargo | Ultrasonic frequency | Therapeutic area | Study |
|---|---|---|---|---|---|
| C6F14 | Alginate | Doxorubicin and curcumin |
28 k Hz and 1 MHz |
Multidrug Resistant Ovarian Cancer | (Baghbani and Moztarzadeh, 2017) |
| C5F12 | PLGA | Cetuximab and 10-Hydroxycamptothecin | 1 MHz | Anaplastic Thyroid Carcinoma | (Wang et al., 2018) |
| C9F20 | Mix of DSPC and mPEG-DSPE | Lidocaine | 2.25 MHz | Acute and Chronic Pain | (Soto et al., 2018) |
| C5F12 | Perylene diimide | ZnF16Pc | 40 MHz | Malignant Glioblastoma | (Tang et al., 2018) |
| C6F14 | Phosphatidyl ethanolamine | Ce6 | 1 MHz | Breast Cancer | (Yu et al., 2018) |
| C3F8 | Mix of DSPE-PEG3400-t Ly P-1, DPPG, DPPC, and cholesterol | 10-Hydroxycamptothecin | 1 MHz | Breast Cancer | (Zhu et al., 2018) |
| C5F12 | Mix of POPC, POPE, cholesterol, and DSPE-PEG-2000 | Camptothecin | 2 MHz | Melanoma | (Ho et al., 2018) |
| C5F12 | Mix of DPPC, DSPE- m PEG2000, cholesterol |
IR780 | 650 k Hz for treatment, 12 MHz for imaging |
Breast Cancer | (Zhang et al., 2019) |
| C6F14 | O-carboxymethyl chitosan | Doxorubicin | 9.0 MHz | Prostatic Cancer | (Meng et al., 2019) |
| C7F16 | Pluronic F68 | Basic fibroblast growth factor | 2.5 MHz | Ischemic Cardiovascular Diseases | (Dong et al., 2019) |
| C6F14 | Polydopamine | No cargo | 7.5 MHz | Breast Cancer | (Mannaris et al., 2020) |